使用网络分析识别乳腺癌患者不同化疗阶段的核心症状:一项前性的多中心纵向研究
Jiali He1, Dingxi Bai1, Huan Chen1
1School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Patient preference and adherence
|February 19, 2026
概括
这项研究确定了接受化疗的乳腺癌患者的核心症状. 干预措施应该首先针对睡眠困难和抑郁症,随后是食欲下降和疼痛,疲劳在后期阶段是主要的.
科学领域:
- 在瘤学瘤学.
- 症状科学 症状科学
- 网络分析 网络分析
背景情况:
- 网络分析有助于识别针对性乳腺癌治疗策略的核心症状.
- 关于乳腺癌患者在不同化疗阶段的症状网络的研究有限.
研究的目的:
- 为了确定乳腺癌患者在不同的化疗阶段进行干预的核心症状.
主要方法:
- 一项多中心前性纵向调查从2022年11月到2023年10月,涉及467名乳腺癌患者.
- 接受化疗的乳腺癌患者的症状评估尺度在四个时间点测量了症状:化疗前 (T0),第一 (T1),第三 (T2) 和第六 (T3) 治疗后.
- 网络分析探索了症状网络和节点属性.
主要成果:
- 在T0时,睡眠困难和抑郁症是关键症状.
- 在T1时,食欲下降和疼痛成为主要问题.
- 疲劳被确定为T2和T3中最主要的症状,在整个过程中观察到稳定的症状网络.
结论:
- 需要干预的核心症状在乳腺癌患者的化疗阶段之间有所不同.
- 有针对性的干预措施应解决睡眠困难和抑郁症 (T0),食欲下降和疼痛 (T1),并优先考虑后期阶段的疲劳管理 (T2,T3).
相关概念视频
Cancer Survival Analysis
788
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
788
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
657
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
657
